4.3 Article

Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice

期刊

LEUKEMIA RESEARCH
卷 51, 期 -, 页码 3-10

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2016.10.005

关键词

Chronic myeloid leukemia; Imatinib; Sokal score; ABCB1/P-glycoprotein; ABCG2; OCT1

资金

  1. Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ-PPSUS) [E-26/110.238/2014]
  2. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [312654/2013-8]
  3. Instituto Nacional de Ciencia e Tecnologia (INCT) [573806/2008-0]
  4. Programa de Oncobiologia (UFRJ/Fundacao do Cancer)

向作者/读者索取更多资源

Despite the favorable clinical evolution of patients with chronic myeloid leukemia (CML), resistance or intolerance to imatinib is present in approximately 35% of patients. Sokal score is a widely used risk factor, however efflux and influx transporters are provisional risk factors implicated in imatinib resistance. This study analyzed Sokal score, ABCB1, ABCG2 and OCT1 mRNA transporter expression levels as well as P-glycoprotein expression and efflux transporters activity to seek a possible correlation between these factors and the molecular response at 12 months from imatinib start as well as 8-year overall survival (OS). Low plus intermediate Sokal score correlated to optimal imatinib responses, as well as OS at 8-years, thus confirming the established role of Sokal score as a prognostic factor in CML patients. Low ABCB1 and high OCT1 mRNA levels were associated with an optimal molecular response, while the inverse levels were associated with non-responders (warning and failure) patients. Our results suggest that ABCB1 and OCT1 mRNA expressions may present biological relevance to identify responder and non-responder patients to imatinib treatment. (C) 2016 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据